Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
5 hedge funds and large institutions have $6.13K invested in Kiromic BioPharma, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1.88% less ownership
Funds ownership: 2.07% → 0.19% (-1.9%)
29% less funds holding
Funds holding: 7 → 5 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
92% less capital invested
Capital invested by funds: $78.2K → $6.13K (-$72.1K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$64.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.72K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$587 |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$26 |
KRBP Hedge Fund Activity: Q2 2023 in Review
5 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q2 2023, worth a combined $6.13K — down 92% from $78.2K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of KRBP and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Wells Fargo, adding an estimated $7. The largest seller was Susquehanna International Group, exiting entirely with an estimated $64.2K sold.
- 5 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q2 2023, down from 7 in Q1 2023.
- Funds reported $6.13K of Kiromic BioPharma, Inc. Common Stock stock for Q2 2023, down 92% quarter-over-quarter.
- 0 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q2 2023 was Wells Fargo, an estimated $7 added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q2 2023 was Susquehanna International Group, an estimated $64.2K sold.
Based on aggregated 13F filings for Q2 2023.